Free Newsletter
Genocea tackles next-gen pneumococcus vaccine
Xconomy's Luke Timmerman profiles the work of Genocea Biosciences, which is developing a low-cost, next-gen pneumococcus vaccine that can outperform the blockbuster Prevnar. Seattle-based PATH has been backing the development program with money from the Gates Foundation. PATH has put up $1 million for a three-year program at Genocea to find new antigens that can be used in a vaccine. Their goal is to do better than Prevnar, which works against only seven of the 80 different types of pneumococcus bacteria. And they want to do it at about $3.50 a dose so that it can be widely available in the developing world. Genocea was a 2008 Fierce 15 winner.
- read the report from Xconomy
Related Articles:
Genocea Biosciences - 2008 Fierce 15
Genocea wins award for in vitro immune system
More stories about Genocea Biosciences
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
